Characteristics of Subjects at Baseline by D3 Dose Group.

*Dose groups significantly different pa n = 59, one subject had unknown HIV acquisitionb n = 40 for subjects c n = 54 subjects with date of diagnosis for HIV (28 in 4000 and 26 in 7000IU/d group)d n = 59 subjects with date of initiation of ART treatment (30 in 4000 and 29 in 7000IU/d group)e n = 56 subjects with HIV CDC classification data and CD4 counts from medical record review (27 in 4000 and 29 in 7000IU/d group)f n = 59 with CD4% baseline (29 in 4000 and 30 in 7000IU/d group)g n = 53 RNA viral load at baseline (26 in 4000 and 27 in 7000IU/d group)h Tenofovir was used only in combination with NNRTI-based regimens.HIV, human immunodeficiency virus; BMI, body mass index; CDC, Center for Disease Control; Clinical categories: N = asymptomatic, A = mildly symptomatic, B = moderately symptomatic, and C = severely symptomatic with AIDS defining illness; CD4 cluster of differentiation; PI, protease inhibitor-based anti-retroviral treatment (ART); NNRTI, non-nucleoside reverse transcriptase-based ART.Characteristics of Subjects at Baseline by D3 Dose Group.